Bio-Rad Laboratories SAS – Trademark Portfolio
Entity Type: 99
Bio-Rad Laboratories SAS holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 8 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EVOLIS and PLATELIA.
3 boulevard Raymond Poincaré
F-92430 MARNES LA COQUETTE
Showing of trademarks Trademarks
Trademark Classifications
Bio-Rad Laboratories SAS's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Bio-Rad Laboratories SAS have?
Bio-Rad Laboratories SAS has 16 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 cancelled.
What trademark classes does Bio-Rad Laboratories SAS file in?
Bio-Rad Laboratories SAS files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Bio-Rad Laboratories SAS's most well-known trademarks?
Bio-Rad Laboratories SAS's registered trademark portfolio includes well-known marks such as EVOLIS and PLATELIA. These are among 2 currently registered trademarks in the portfolio.
What is Bio-Rad Laboratories SAS's trademark registration success rate?
Bio-Rad Laboratories SAS has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.